I found the most 'expensive', profitable ASX All Ords share: rip-off or bargain?

A single number in isolation can be dangerous to an investor's decision making.

| More on:
A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Have you ever wondered which ASX All Ords share holds the trophy for the highest price-to-earnings (P/E) ratio? More importantly, does its supreme premium make it an investors' nightmare by default?

In the world of investing, P/E ratios are often used as the go-to yardstick for determining value. Investors will compare a company's earnings multiple to peers, its industry average, or an index. If it's below those, then it's apparently cheap — and if it's above, it's expensive.

It is a reductive analysis, yet widely used.

So, is Chrysos Corporation Ltd (ASX: C79) overvalued if its P/E is 1,364 times?

Why this ASX All Ords share appears 'expensive'

Chrysos Corporation joined the All Ords index in the March 2023 quarterly rebalance. The company provides an alternative assay solution for determining the content of gold, silver, or copper from ore samples.

The method of putting samples under an X-ray is Chrysos' improvement upon the ancient fire assay procedure. This patented technology is bundled into an assaying machine called the PhotonAssay, deployed and leased to miners and testing laboratories in Australia, North America, and Africa.

Obviously, the elephant in the room is the 1,364 times earnings multiple this company trades on. As shown in the table below, this is almost two orders of magnitude greater than peers and the broader index.

ComparisonP/E Ratio
Chrysos Corporation1,364
Australian commercial services industry17.4
S&P/ASX All Ordinaries Index (ASX: XAO)19.3

Such a P/E ratio would send a traditional value investor running for the hills. However, there's more here than meets the eye.

The earnings multiple is distorted due to Chrysos achieving net profits after tax (NPAT) marginally above breakeven at $443,000.

Crucially, this isn't a company that has reported flat revenue for five years and is regularly posting sub-$1 million earnings. In FY23, Chrysos grew its top-line figure by 89% compared to the prior year. Likewise, management expects to dial this up another 98% in FY24 at its revenue guidance midpoint.

Could it still be worth buying?

The extent to which this ASX All Ords share constitutes a buy depends on a personal deduction of intrinsic value. It truly comes down to what seems like a likely rate of growth for this company in the future.

As legendary investor Terry Smith once shared, "The level of valuation which may represent good value at which to buy shares in a high-quality company may surprise you."

One such example I own is Pro Medicus Limited (ASX: PME). Rarely has the company traded on a P/E less than 60 in the last seven years. Yet, you could have purchased shares in the medical imagining software company at nearly any time in its history and made money.

Source: TradingView

In FY16, Pro Medicus made $6.4 million in earnings. Fast forward seven years, and it's making nearly ten times as much, as shown above.

The rate of adoption/utilisation of Chrysos' PhotonAssay will be an essential metric to track. If it can become a widespread replacement for fire assays and expand into other commodities, it might shake off the perception of an 'expensive' ASX All Ords share.

In many ways, the Chrysos story looks similar to Pro Medicus… but that's an article for another day.

Should you invest $1,000 in Chrysos Corporation Limited right now?

Before you buy Chrysos Corporation Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Chrysos Corporation Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Mitchell Lawler has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Chrysos and Pro Medicus. The Motley Fool Australia has positions in and has recommended Chrysos. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A businessman holding a world globe in one hand, representing global investment.
Growth Shares

3 exciting ASX growth shares with massive long-term potential

Analysts think these buy-rated growth shares could have significant potential.

Read more »

A woman wearing a hard hat holds two sparking wires together as energy surges between them. representing the rising Li-S Energy share price today
Growth Shares

Supercharge your wealth with these buy-rated ASX growth shares

Analysts say that these shares would be great picks for growth investors.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Growth Shares

3 ASX growth shares down 30% or more to buy right now

Analysts are expecting these shares to rebound strongly from recent weakness.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Growth Shares

3 fantastic ASX 200 growth shares to buy with $20,000

Brokers think these shares are going places. Let's see what they are.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Growth Shares

1 magnificent ASX stock down 33% to buy and hold forever

Analysts think that this fallen angel could be a quality buy right now.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Growth Shares

Got $2,000 to invest? These ASX shares could rise 30% to 60%

Analysts are tipping these shares to rise strongly from current levels.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Growth Shares

Macquarie tips these ASX growth shares as buys

The broker is feeling bullish about these top shares. Let's see why.

Read more »